Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20383692rdf:typepubmed:Citationlld:pubmed
pubmed-article:20383692lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:20383692lifeskim:mentionsumls-concept:C2239176lld:lifeskim
pubmed-article:20383692lifeskim:mentionsumls-concept:C0040648lld:lifeskim
pubmed-article:20383692lifeskim:mentionsumls-concept:C2347610lld:lifeskim
pubmed-article:20383692lifeskim:mentionsumls-concept:C0449258lld:lifeskim
pubmed-article:20383692lifeskim:mentionsumls-concept:C0591833lld:lifeskim
pubmed-article:20383692pubmed:issue8lld:pubmed
pubmed-article:20383692pubmed:dateCreated2010-7-9lld:pubmed
pubmed-article:20383692pubmed:abstractTextHepatocellular carcinoma (HCC) is a hypervascularized tumor entity with association of arterial vessel density with poor prognosis. The hypoxia-inducible transcription factor HIF-1alpha represents a pivotal regulator of angiogenesis and is thought to determine the angiogenic nature of HCC. However, the precise role of HIF-1alpha during the pathogenesis of HCC remains elusive. We established a functional inactivation of HIF-1alpha in vitro and in vivo via RNAi and Cre/loxP-mediated recombination, respectively, to determine HIF-1alpha's role for tumor growth and chemosensitivity in transgenic and orthotopic murine HCC models. HIF-1alpha-deficient HCC cells displayed significantly reduced anchorage-independent growth and enhanced sensitivity toward etoposide, while basic cellular proliferation was unaffected. Analysis of gross tumor growth failed to detect reduced growth of HIF-1alpha-deficient tumors in the orthotopic and the transgenic HCC model, respectively. In line with the in vitro data, treatment of HIF-1alpha-deficient tumors with etoposide resulted in greater antiproliferative efficacy when compared to wild-type mice. Taken together, our study does not support a pivotal role of HIF-1alpha for tumor growth and angiogenesis in two murine HCC models. However, our data point toward a significant function of HIF-1alpha in determining chemosensitivity of HCC and therefore warrant validation of HIF-1alpha-inhibitors as adjuvant therapeutic agents in clinical studies of human HCC.lld:pubmed
pubmed-article:20383692pubmed:languageenglld:pubmed
pubmed-article:20383692pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20383692pubmed:citationSubsetIMlld:pubmed
pubmed-article:20383692pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20383692pubmed:statusMEDLINElld:pubmed
pubmed-article:20383692pubmed:monthAuglld:pubmed
pubmed-article:20383692pubmed:issn1432-1440lld:pubmed
pubmed-article:20383692pubmed:authorpubmed-author:WiedenmannBer...lld:pubmed
pubmed-article:20383692pubmed:authorpubmed-author:SchmitzVolker...lld:pubmed
pubmed-article:20383692pubmed:authorpubmed-author:LoddenkemperC...lld:pubmed
pubmed-article:20383692pubmed:authorpubmed-author:CramerThorste...lld:pubmed
pubmed-article:20383692pubmed:authorpubmed-author:DupuyEvelyneElld:pubmed
pubmed-article:20383692pubmed:authorpubmed-author:RaskopfEsther...lld:pubmed
pubmed-article:20383692pubmed:authorpubmed-author:KühlAnjaAlld:pubmed
pubmed-article:20383692pubmed:authorpubmed-author:DaskalowKatja...lld:pubmed
pubmed-article:20383692pubmed:authorpubmed-author:RohwerNadineNlld:pubmed
pubmed-article:20383692pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20383692pubmed:volume88lld:pubmed
pubmed-article:20383692pubmed:ownerNLMlld:pubmed
pubmed-article:20383692pubmed:authorsCompleteYlld:pubmed
pubmed-article:20383692pubmed:pagination817-27lld:pubmed
pubmed-article:20383692pubmed:dateRevised2011-7-8lld:pubmed
pubmed-article:20383692pubmed:meshHeadingpubmed-meshheading:20383692...lld:pubmed
pubmed-article:20383692pubmed:meshHeadingpubmed-meshheading:20383692...lld:pubmed
pubmed-article:20383692pubmed:meshHeadingpubmed-meshheading:20383692...lld:pubmed
pubmed-article:20383692pubmed:meshHeadingpubmed-meshheading:20383692...lld:pubmed
pubmed-article:20383692pubmed:meshHeadingpubmed-meshheading:20383692...lld:pubmed
pubmed-article:20383692pubmed:meshHeadingpubmed-meshheading:20383692...lld:pubmed
pubmed-article:20383692pubmed:meshHeadingpubmed-meshheading:20383692...lld:pubmed
pubmed-article:20383692pubmed:meshHeadingpubmed-meshheading:20383692...lld:pubmed
pubmed-article:20383692pubmed:meshHeadingpubmed-meshheading:20383692...lld:pubmed
pubmed-article:20383692pubmed:meshHeadingpubmed-meshheading:20383692...lld:pubmed
pubmed-article:20383692pubmed:meshHeadingpubmed-meshheading:20383692...lld:pubmed
pubmed-article:20383692pubmed:meshHeadingpubmed-meshheading:20383692...lld:pubmed
pubmed-article:20383692pubmed:year2010lld:pubmed
pubmed-article:20383692pubmed:articleTitleRole of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma.lld:pubmed
pubmed-article:20383692pubmed:affiliationMedizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.lld:pubmed
pubmed-article:20383692pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20383692pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:3091entrezgene:pubmedpubmed-article:20383692lld:entrezgene
entrez-gene:15251entrezgene:pubmedpubmed-article:20383692lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:20383692lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:20383692lld:entrezgene